Treatment with statins: Further data from the heart protection study;Videre belysning av statinbehandling: Heart protection study

Tidsskrift for den Norske Laegeforening

Volumn 122, Issue 29, 2002, Pages 2777-2780

  Tonstad, Serena ^a   Holme, Ingar ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART INFARCTION; HEART PROTECTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; POSTMENOPAUSE; RISK ASSESSMENT; TREATMENT INDICATION;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; LOVASTATIN; MALE; META-ANALYSIS; MIDDLE AGED; PRAVASTATIN; PRIMARY PREVENTION; RISK FACTORS; SIMVASTATIN;

EID: 0037202728     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al for the Cholesterol And Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 355: 1001-9.
4. The Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Resuits of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
6. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999; 20: 725-41.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
8. Katholi RE, Deitrick CL, Hardiek KJ. If LDLC is the answer... what was the question? What do the data really show? Heart Dis 2001; 3: 2-13.
9. Thompson GR, Packard CJ, Stone NJ. Goals of statin therapy: Three viewpoints. Curr Atheroscler Rep 2002; 4: 26-33.
10. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995; 76 (suppl): 10C-7C.
11. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Circulation 1998; 97: 946-52.
12. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19: 187-95.
13. Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RAH et al on behalf of the LIPID Study Investigators. Relationship between lipid levels and clinical outcomes in the LongTerm Intervention with Pravastatin in Ischemic Disease (LIPID) trial. Circulation 2002; 105: 1162-9.
14. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K et al for the Scandinavian Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-60.
15. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins M et al for the Prospective Pravastatin Pooling Project Investigators Group. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000; 102: 1893-900.
16. Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97: 1446-52.
17. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
18. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9.
19. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20.
20. Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O et al for the Scandinavian Simvastatin Study Group. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation 1997; 96: 4211-8.
21. Lewis SJ, Moyé LA, Sacks FM, Johnston DE, Timmis G, Mitchell J et al for the CARE investigators. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) Trial. Ann Intern Med 1998; 129: 681-9.
22. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ et al for the CARE investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucoseintolerant myocardial infarction survivors with average cholesterol levels. Circulation 1998; 98: 2513-9.
23. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8.
24. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303: 276-82.
25. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med 1997; 336: 153-62.
26. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM et al for the Atorvastatin versus Revascularization treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-6.
27. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150: 341-53.
28. Terapianbefaling: behandling av hyperlipidemi. SLK-publikasjon 2000: 6. Oslo: Statens legemiddelkontroll, 2000.
29. Feely J, McGettigan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. Clin Pharmacol Ther 2000; 67: 438-41.
30. Sirtori CR, Calabresi L, Marchioli R, Rubins HB. Cardiovascular risk changes after lipid lowering medications: Are they predictable? Atherosclerosis 2000; 152: 1-8.
31. Wood R, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.